[The Cutting-edge of Medicine: Pathophysiology and Management of thrombotic thrombocytopenic purpura].
作者信息
Yagi Hideo, Matsumoto Masanori
出版信息
Nihon Naika Gakkai Zasshi. 2015 Mar 10;104(3):607-14. doi: 10.2169/naika.104.607.
PMID:26571751
Abstract
摘要
相似文献
1
[The Cutting-edge of Medicine: Pathophysiology and Management of thrombotic thrombocytopenic purpura].
Nihon Naika Gakkai Zasshi. 2015 Mar 10;104(3):607-14. doi: 10.2169/naika.104.607.
2
Thrombotic thrombocytopenic purpura: advances in pathophysiology, diagnosis, and treatment--introduction.
Semin Hematol. 2004 Jan;41(1):1-3. doi: 10.1053/j.seminhematol.2003.11.001.
3
[Thrombotic thrombocytopenic purpura].
Rinsho Ketsueki. 2012 Feb;53(2):185-95.
4
[Recent therapeutic strategy for thrombotic thrombocytopenic purpura].
Rinsho Ketsueki. 2014 Jan;55(1):93-104.
5
Pathophysiology of thrombotic thrombocytopenic purpura.
Int J Hematol. 2010 Jan;91(1):1-19. doi: 10.1007/s12185-009-0476-1.
6
[Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
Rinsho Byori. 2015 Oct;63(10):1228-36.
7
ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
Annu Rev Med. 2015;66:211-25. doi: 10.1146/annurev-med-061813-013241.
8
[Treatment of thrombotic thrombocytopenic purpura].
Rinsho Ketsueki. 2014 Oct;55(10):2076-86.
9
The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasma.
Transfusion. 2006 Jan;46(1):74-9. doi: 10.1111/j.1537-2995.2005.00674.x.
10
The role for adjunctive treatment to plasma exchange in thrombotic thrombocytopenic purpura.
Nephrol Dial Transplant. 2008 Aug;23(8):2701-2; author reply 2702-3. doi: 10.1093/ndt/gfn173. Epub 2008 Apr 10.
Zotero 插件